Pooled data from three Phase 2 triple‑blind crossover trials show that MDMA‑assisted psychotherapy (75–125 mg) produced significantly greater posttraumatic growth (Hedges’ g = 1.14) and larger PTSD symptom reductions (Hedges’ g = 0.88) at the primary endpoint versus placebo/low‑dose control. These gains persisted to 12‑month follow‑up—with higher PTG, lower symptom scores and 67.2% no longer meeting PTSD criteria—suggesting PTG may be a meaningful mechanism of treatment effect.
- Published
- Journal
- Journal of Traumatic Stress
- Authors
- Gorman, I., Belser, A. B., Jerome, L., Hennigan, C., Shechet, B., Hamilton, S., Yazar-Klosinski, B., Emerson, A., Feduccia, A. A.